XTL Biopharmaceuticals Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of December 2025 for XTL Biopharmaceuticals Ltd., a foreign private issuer headquartered in Ramat Gan, Israel. The report is filed pursuant to Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes and Events
On December 24, 2025, the Company received a notification letter from The Listing Qualifications Department of The Nasdaq Stock Market LLC. The notification cites a deficiency regarding the Company's minimum bid price, indicating the stock price has fallen below the required threshold for continued listing.
Outlook, Risks, and Management Commentary
The filing incorporates a press release (Exhibit 99.1) detailing the Nasdaq notification. No specific guidance, management commentary on future operations, or discussion of other risks and contingencies is included in the body of this specific filing text.
Investor Verification Checklist
- Verify the current trading price of XTL Biopharmaceuticals Ltd. stock against Nasdaq's minimum bid price requirement.
- Review the full text of the press release dated December 24, 2025 (Exhibit 99.1) for details on the deficiency notice.
- Check for any subsequent filings or announcements regarding a plan to regain compliance with Nasdaq listing standards.
- Confirm the timeline provided by Nasdaq for the Company to demonstrate compliance.